Tag Archives: Two New Alzheimer’s Amyloid Drugs: A Prediction

Two New Alzheimer’s Amyloid Drugs: A Prediction

Majid Ali, M.D. No Benefits for Patients, Enormous Riches for Drug Makers On July 23, 2015, The New York Times printed a story about two amyloid drugs for treating Alzheimer’s disease: solanezumab and solanezumab. Here is the basis of my prediction. Amyloid protein deposits in the brain result from brain toxicities and pathologic immune responses to them. The main lesson

Read more